The following FAQs are listed by topic in alphabetical order for reference. Topics include website links as information changes quickly. The date following each link refers to the CDC update used in this FAQ.

These FAQs can relate to a home health, hospice, private duty, infusion, palliative care or DMEPOS providers. Updates made to are noted in red to make it easier to see changes.

If you have questions or comments, please send them to education@chapinc.org Thank you!!

April 22, 2021: The Federal Public Health Emergency Extended to July 21, 2021: Secretary Xavier Becerra has extended the PHE effective April 21, 2021 for 90 days or mid-July. The Biden Administration also sent a letter to the governors advising that 60-day notice will be given when the PHE will end. https://ccf.georgetown.edu/wp-content/uploads/2021/01/Public-Health-Emergency-Message-to-Governors.pdf Jan 22 2021

A

Assisted and Independent Living Facility Access:
Check your state to determine if the governor or health department has mandated staff COVID-19 testing for ALFs. Home health and hospice staff are included in mandated testing as home care or hospice staff are a ‘vendor’. Weekly or bi-weekly COVID 19 testing may be required.

CMS addresses Home Health Agency (HHA) and Hospice access to assisted (ALF) and independent living facilities (ILF) and when Hospices should Discharge Patients if Restricted or No Access
• ALFs and ILFs are not subject to federal regulation, rather state authority.
• Hospice and HHA personnel are expected to participate in any facility required screening.
• If access is restricted, hospices and HHAs should communicate with the facility administration about the nature of the restriction and gaining access to hospice or home care patients.
• HOSPICE DISCHARGE: If after reasonable attempts are made to access hospice patients in person and documented in the patient’s record, the hospice is expected to discharge the patient as “outside of the hospice’s service area” (Medicare Benefit Policy Manual, Chapter 9, 20.2.3):
  • Additionally, a hospice must forward to the patient’s attending physician a copy of the hospice discharge summary and patient’s clinical record if requested.


(March 10 Memo Revised April 23, 2020. Note the HHA reference to ALF/ILF access on page 6)
C

COVID-19 – Updates

Current Infection Rates per 100K Population, Variants of Concern and Breakthroughs:

June 24 - New COVID-19 Cases per Week

- The 7-day average of new cases has decreased by 10%. The current 7-day moving average of daily new cases (13,997) decreased 6% compared with the previous 7-day moving average (14,890).
- The US is 94% below Jan 2021 peak of 252,768.
- High Infection Risk States: Missouri (78K/100K); WY (68/100K); UT (new) 64 cases/100k, NV (new) 63 cases/100K; Arkansas new (54 cases/100K); CO (48 cases/100k); Louisiana (48 cases/100K), FL (48 cases/100K). New = new to the list due to a surge in the preceding 7 days. The infection rate of all states listed is 2X > than the national median.  
https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days June 23, 2021

Variants:

- Viruses constantly change through mutation. CDC monitors variants of concern (VOC) that have mutations that cause the virus to act in ways that are significant to public health (e.g., more severe disease, spreads more easily between humans, requires different treatments, or may change vaccine effectiveness).
- There are 3 variant levels: Variant of Interest, Variant of Concern, Variant of High Consequence
- June 24, 2021: New Variant of Concern: The Delta variant (B.1.167.2) first discovered in India now represents 21.6% of US cases increasing from 2.7% in May and doubling in the past two weeks. Expected to become dominant in the next month. Variant is more easily transmissible and can cause more severe disease.
- Variants of Concern circulating in the US: UK (B.1.1.7-alpha variant representing 52% of cases); Brazil/Japan (P.1 -gamma 16% of cases); B.1.351 (South Africa-beta): B.1.427 and B.1.429 California (epsilon). All have 20-50% increase in transmissibility.

- Vaccination is the best response to variants:

June 24, 2021: Fully Vaccinated in US – (note significant variation by county in the US)

<table>
<thead>
<tr>
<th>Fully Vaccinated in US Adults: 18 and older</th>
<th>One Dose of 2 doses of adults 18 and older</th>
<th>Fully Vaccinated 12 and older:</th>
<th>Fully Vaccinated 65 and older</th>
</tr>
</thead>
<tbody>
<tr>
<td>56.1%</td>
<td>65.6%</td>
<td>53.1%</td>
<td>77.3%</td>
</tr>
</tbody>
</table>

https://covid.cdc.gov/covid-data-tracker/#vaccinations June 24, 2021

Studies are continuing in Europe on the effectiveness of the 3 vaccines, early results indicate that they remain 88-92% effective after being fully vaccinated. No vaccine is 100% effective.
**Breakthrough Infection:**

**COVID-19 Breakthrough Infection Among Fully Vaccinated Individuals Only Reported by CDC if Infection Results in Hospitalization or Death as of May, 2021**

- A vaccine breakthrough case definition: A person who has SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥ 14 days after being fully vaccinated.
- Current data suggest that COVID-19 authorized vaccines protect against most SARS-CoV-2 variants in the US. However, variants will cause some of these vaccine breakthrough cases.
- CDC monitors reported breakthrough cases including time since vaccination, vaccine type or lot number and if possible, respiratory specimens to identify genomic sequencing associated with the infection.
- **JUNE 24, 2021,** As of June 14, 2017, among 144 million fully vaccinated people in the US, 3,276 had breakthrough case of COVID-19 that resulted in hospitalization and/or death.
  - 77% were among people ≥65 years of age, primarily female (49%)
  - 95% hospitalized and 18% died.

[https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html](https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html) June 18, 2021

**COVID-19 Adult Signs and Symptoms:**

People with COVID-19 have had a wide range of symptoms reported – ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. Anyone can have mild to severe symptoms. People with these symptoms may have COVID-19:

<table>
<thead>
<tr>
<th>Fever or chills</th>
<th>Cough</th>
<th>Headache</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle or body aches</td>
<td>Sore Throat</td>
<td>Shortness of Breath or difficulty breathing</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Congestion or Runny Nose</td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>New loss of smell and taste</td>
<td>Nausea or vomiting</td>
</tr>
</tbody>
</table>

**Lost of taste and smell may persist for weeks or months after recovery and need not delay the end of isolation.** [https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html) Feb 22, 2021

**CDC Clinician On-Call Center** is a hotline with trained CDC clinicians available to answer COVID-19 questions daily on a wide range of topics, such as diagnostic challenges, clinical management, and infection prevention and control. To reach this service, call 800-CDC-INFO (800-232-4636) and ask for the Clinician On-Call Center.

**COVID 19 Illness Severity Ranges from Mild to Severe Update:**

- Mild to moderate disease (absence of viral pneumonia or hypoxia) Most able to manage illness at home and self-isolate.
- Severe (most common symptoms – pneumonia, ARDS, sepsis and septic shock, cardiomyopathy and arrhythmia, acute kidney failure, GI bleeding) Requiring hospitalization for management.

FAQs: COVID 19 Conference Calls

Updated June 24, 2021

Update of Medical Conditions in Adults Who are at risk of Severe Illness from COVID 19


<table>
<thead>
<tr>
<th>Cancer</th>
<th>Overweight (BMI &gt; 25kg/m but &lt; 30kg/m), Obesity (BMI 30kg/m but &lt; 40 kg/m), Severe obesity (BMI &gt; 40kg/m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic Kidney Disease</td>
<td>Pregnancy</td>
</tr>
<tr>
<td>Chronic lung disease: including COPD, emphysema, and chronic bronchitis, moderate to severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension</td>
<td>Smoking, Current or Former</td>
</tr>
<tr>
<td></td>
<td>Solid Organ or Blood Stem Cell Transplant</td>
</tr>
<tr>
<td></td>
<td>Stroke or cerebrovascular disease affecting blood flow to the brain</td>
</tr>
<tr>
<td>Heart conditions such as heart failure, CAD, cardiomyopathies, or hypertension</td>
<td>Immune compromised state (weakened immune system)</td>
</tr>
<tr>
<td>Diabetes – Type 1 or 2</td>
<td>Sickle Cell Disease or thalassemia</td>
</tr>
<tr>
<td>Dementia or other neurological conditions including Alzheimer’s</td>
<td>Down Syndrome</td>
</tr>
<tr>
<td></td>
<td>Substance Use Disorders</td>
</tr>
<tr>
<td>HIV Infection</td>
<td>Liver disease: alcoholic related or nonalcoholic fatty liver disease, cirrhosis and scarring of the liver.</td>
</tr>
</tbody>
</table>

COVID-19 Population by Age by Risk for Hospitalization and Death Update

<table>
<thead>
<tr>
<th>Age Range</th>
<th>Hospitalization</th>
<th>Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-17 yrs.</td>
<td>Comparison Group</td>
<td>Comparison Group</td>
</tr>
<tr>
<td>18-29 yrs.</td>
<td>6x higher</td>
<td>10x higher</td>
</tr>
<tr>
<td>30-39 yrs.</td>
<td>10x higher</td>
<td>45x higher</td>
</tr>
<tr>
<td>40-49 yrs.</td>
<td>15x higher</td>
<td>130x higher</td>
</tr>
<tr>
<td>50-64 yrs.</td>
<td>25x higher</td>
<td>440x higher</td>
</tr>
<tr>
<td>65-74 yrs.</td>
<td>40x higher</td>
<td>1300x higher</td>
</tr>
<tr>
<td>75-84 years</td>
<td>65x higher</td>
<td>3220x higher</td>
</tr>
<tr>
<td>85+ years</td>
<td>95x higher</td>
<td>8700x higher</td>
</tr>
</tbody>
</table>

Transmission Risk:

Airborne Transmission Risk for COVID 19:
SARS-CoV-2 is transmitted by exposure to infectious respiratory fluids, most commonly by people inhaling very small respiratory droplets. The risk of becoming infected with SARS-CoV-2 varies according to the amount of virus to which a person is exposed, distance from the source, and ventilation in the space.


COVID-19 Transmission Risk through Contaminated Surfaces:
It is possible for people to be infected through contact with contaminated surfaces or objects (fomites), but the risk is generally considered to be low. Research has confirmed that the COVID-19 virus can degrade quickly upon contact with surfaces. The risk for contamination is based on the following:

- The infection prevalence rate in the community
- The amount of virus that people known to be infected with COVID 19 expel for an example in a cough or sneeze.
- The accumulation of expelled virus particles onto surfaces, which is affected by air flow and ventilation, and the efficiency of transferring those virus particles from the surfaces to the mucous membranes on the face (nose, mouth, eyes).


What Can Be Done to Reduce Risk of Transmission from Contaminated Surfaces:

- Ask unvaccinated visitors to wear masks.
- Isolate people who are sick with COVID-19
- Have everyone in the household, and staff (including those in the office) wash hands often, especially when returning from outside.
- Remind folks about cough and sneeze etiquette.
- Use the two-step process when cleaning:
  1) Clean visibly dirty surfaces with household cleaners containing soap or detergent.
  2) Then disinfecting using a disinfectant that is known to be effective against COVID 19, see below.


Disinfectants Effective for Surfaces Contaminated with COVID-19 – EPA website Made Easier to Use Table N

- Video and infographic on how to use EPA product Table N.

List N https://www.epa.gov/pesticide-registration/list-n-disinfectants-coronavirus-covid-19

Ventilation-the Next Element in Reducing Transmission Inside Buildings:
The next layer of protection from spreading the Virus is ventilation inside homes and office. The issue

- For homes, better ventilation means primarily open windows and increase use of fans.
- CDC site noted below also includes specific technologies information including such items as ultraviolet germicidal irradiation (UVGI), otherwise known as germicidal ultraviolet (GUV). It is a disinfection tool
used in many different settings, such as residential, commercial, educational, and healthcare settings and is effective with COVID-19. Issues is finding a reliable UVGI manufacturer. Also how protective barriers may impact ventilation under FAQs.


Children and COVID 19 –
Children can be infected with COVID-19, can get sick from COVID-19, and can spread the virus to others. Children who have COVID-19 but have no symptoms (“asymptomatic”) can still spread the virus to others. Most children with COVID-19 have mild symptoms or no symptoms at all.

Pediatric Patients 17 yrs. and Younger- COVID 19 Incidence Update:
• May 6, 2021: 3.5M cases in children (17yrs or younger) representing 14% of all COVID cases.
• 0.1 to 1.9% of reported pediatric cases resulted in hospitalization; mortality 0-0.03% among reporting states, no change in proportions over the past two quarters.
• 7 states report that children are >18% of state’s COVID cases: ME, MN, NM, SC (sustained 5 months); TN (sustained 5 months); VT, NM (sustained 5 months)


Conditions of Children at Increased Risk for Severe COVID 19 Illness also Applies to Babies of <1 yr. old: obesity, genetic neurologic or metabolic conditions, sickle cell disease, congenital (since birth) heart disease, diabetes, asthma and other chronic lung disease, and immunosuppression due to malignancy or immune-weakening medications, medical complexity (children with multiple chronic conditions that affect many parts of the body or are dependent on technology or other significant supports for daily life.


Symptoms of COVID 19 in Children:
Symptoms can look like symptoms of other common illnesses such as colds, strep throat, or allergies. The most common symptoms of COVID-19 in children are fever and cough, but children may have any of these signs or symptoms of COVID-19:

<table>
<thead>
<tr>
<th>Fever or chills</th>
<th>Cough</th>
<th>Nausea, vomiting</th>
<th>Diarrhea</th>
<th>Sore throat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomachache</td>
<td>Tiredness</td>
<td>Shortness of Breath, Difficulty Breathing</td>
<td>Headache</td>
<td>Poor appetite or feeding in baby &lt;1 yr. old</td>
</tr>
<tr>
<td>Muscle or Body aches</td>
<td>Nasal congestion runny nose</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


MISC-C: Multisystem Inflammatory Syndrome in Children:
Multisystem inflammatory syndrome in children (MIS-C) is a rare, serious condition where different body parts become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. The cause of MIS-C is not known. Children with the disease test positive for COVID-19 or have been around someone with COVID-19. [https://www.cdc.gov/mis-c/](https://www.cdc.gov/mis-c/)

**Update: CDC information about MIS-C:**

- CDC has reports of 3742 confirmed cases of MIS-C and 35 deaths (<1%)
- MIS-C reported in all states except Vermont and Maine. Most cases reported in California (sustained 6 months), Florida (sustained 6 months).
- 99% of children tested positive for COVID 19, 1% were around someone with confirmed COVID-19.
- 50% of cases are among children aged 5-9, *with the average age of 9.*
- 63% of reported cases in children who are Hispanic or Latino, or Non-Hispanic Black
- 60% of reported cases are male. [https://www.cdc.gov/mis-c/cases/index.html](https://www.cdc.gov/mis-c/cases/index.html) May 3, 2021

**Symptoms of MIS-C Requiring Emergency Care:** **NOTE:** Not all children have all the same symptoms.

<table>
<thead>
<tr>
<th>Trouble breathing</th>
<th>Inability to wake or stay awake</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain or pressure in the chest that does not resolve</td>
<td>Pale, gray or bluish colored skin, lips, nail beds depending on skin tone</td>
</tr>
<tr>
<td>New confusion</td>
<td>Severe abdominal pain</td>
</tr>
</tbody>
</table>


**CDC Guidance for Other Community Settings**

FAQs: COVID 19 Conference Calls

Updated June 24, 2021

D
Disaster Shelters and COVID 19

CDC Guidelines for Disaster Shelters During the Pandemic: The CDC has released guidelines for state and county governments when opening shelters due to disasters (e.g., hurricanes, flooding, etc.).

- Shelters with 50 or less people should be prioritized over large congregate shelters.
- Daily symptom screening, and isolation area for those with COVID symptoms.
- The CDC preference is that vulnerable individuals are not moved to a shelter but remain at home.
- Medical support shelters and functional needs shelters may be available for the more vulnerable populations during disasters.


F
FDA Safety Communication Regarding Over-the Counter Pulse Oximeters: February 19, 2021

Concern about the growing number of purchases of over the counter (OTC) pulse oximeters during the pandemic as these products have serious limitations including inaccurate readings. OTC pulse oximeters do not undergo FDA approval or clinical testing and are not intended for medical purposes.

The FDA has issued a safety communication to pay close attention to all health symptoms, particularly shortness of breath or low oxygen levels rather than rely solely upon the readings of a pulse oximeter. These symptoms include.

- Bluish coloring in the face, lips, or nails;
- Shortness of breath, difficulty breathing, or a worsening cough.
- Restlessness and discomfort
- Chest pain or tightness
- Fast or racing pulse rate.

CAUTION: Some patients with low oxygen levels may not show any of these symptoms.

- Education regarding appropriate use of pulse oximeters should include:
  - Follow the manufacturer’s instructions for use.
  - Remove any fingernail polish.
  - Make sure your hand is warm when placing the oximeter on your finger.
  - Keep the hand relaxed and held below heart level.
  - Sit still and wait a few seconds until the reading stops changing and displays one steady number.
  - Write the oxygen level with the date and time of the reading for easy tracking of changes and trends.
    - It is often more meaningful to look at changes/trends over time than one single reading.

Flu Vaccination and COVID Resource – Update Post 2020-2021 Flu Season
Ensuring immunization services are maintained or reinitiated is essential for protecting individuals and communities from vaccine-preventable diseases and outbreaks and reducing the burden of respiratory illness during the upcoming influenza season.

The following website is a collection of federal resources designed to guide vaccine planning during the COVID-19 pandemic.  
https://www.cdc.gov/vaccines/pandemic-guidance/index.html  April 6, 2021

H
Herd Immunity –
The United States would need 80% of Americans not susceptible to the virus to achieve herd immunity. Per Dr. Fauci, the goal now is to increase vaccination levels to be able to keep serious infections at a manageable level and keep hospitalizations and deaths as low as possible.

M
**CDC Masking Guidelines for Fully Vaccinated Individuals Do Not Apply to Healthcare Settings:**
In general, fully vaccinated healthcare staff should continue to wear PPE while providing care/services. The use of PPE for healthcare staff remains unchanged.

Masking Update for fully Vaccinated Individuals:  CDC provides a quick guide infographic at: **This is not for healthcare settings.**  https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.html  
May 28, 2021

N
**Nursing Home CMS Regulations for Vaccination and Reporting – Including Hospice and Home Care Staff effective May 21, 2021:**  CMS has published a proposed rule for comment that puts in place the following regulations **effective May 21, 2021.** Comments due July 12, 2021  

**Key Points of the new Rule for LTC facilities and ICFs-IID facilities impacting Home Health and Hospice:**
- The rule establishes penalties for non-compliance with the provisions.
- COVID-19 vaccines, when available, must be offered to all residents, clients, and staff - **defined as individuals who work in the facility on a regular (at least once a week) basis** – including nurses, aides, hospice staff, therapists (physical, occupational), physicians and licensed independent practitioner, mental health therapist, volunteers, and other health care providers.
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

- LTC facilities must report COVID-19 vaccination status of residents and staff to the Centers for Disease Control and Prevention (CDC) database NHSN on a weekly basis.
- LTC and ICF facilities must offer and document COVID 19 education to all facility residents, clients and staff covering:
  - the benefits of vaccination, and the
  - risks associated with vaccination including potential side-effects of the vaccine such as aches or fever, as well as rare reactions such as anaphylaxis.

Updated Nursing Home Staff and Resident Testing Guidelines: The federal regulations addressing testing scope and frequency are in addition to any state required testing and any facility-specific testing. The federal publication with detail has been updated 4/27/21.

Key points of testing changes:
- If a symptomatic individual is identified, staff testing applies to vaccinated and unvaccinated individuals if they have symptoms.
- Outbreak (any new case in a facility): all staff are tested, vaccinated and unvaccinated, until no new cases identified.
- Routine testing of unvaccinated staff should be based on the extent of the virus in the facility’s county. Fully vaccinated staff do not have to be routinely tested.
- Facilities must have procedures in place to address staff who refuse testing. Procedures should ensure that staff who have signs or symptoms of COVID-19 and refuse testing are prohibited from entering the building until the return-to-work criteria are met.

Workers who are not employees of the facility but provide direct care to the facility’s residents, such as hospice workers, social workers, clergy etc., must be permitted to come into the facility if they are not subject to a work exclusion due to an exposure to COVID-19 or show signs or symptoms of COVID-19 after being screened. All staff must comply with COVID-19 testing requirements.

Nursing Home (ICF) and SNF Revised Visitation
CMS with the CDC have updated visitation guidance still emphasizing maintaining infection prevention practices, including maintaining at least 6 feet between people and wearing masks - noting the continued risk of COVID-19 transmission. Note: states may have their own guidance.

NOTE: Continued screening for temperature, signs, or symptoms of COVID 19, or close contact with a person who is confirmed COVID 19 in the past 14 days is still recommended for all who enter regardless of the visitor’s vaccination status.
- “Fully vaccinated” is defined by CDC as a person who is ≥2 weeks following receipt of the second dose in a 2- dose series, or ≥2 weeks following receipt of one dose of a single-dose vaccine.
- Outdoor visitation is preferred even if resident and others are fully vaccinated.
- Indoor visitation should be always allowed and for all residents -regardless of vaccination status.
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

- If a resident is fully vaccinated, they can have close contact (including touch) with their visitor while wearing a well-fitting face mask and performing hand-hygiene before and after.
- Compassionate care visits and visits required under federal disability rights law should be always allowed, for any resident -vaccinated or unvaccinated.

Exceptions to Indoor LTC Visitation- An Outbreak which is a new onset of COVID-19. One new COVID-19 case among residents or staff and the facility should immediately begin outbreak testing and suspend all visitation (except that required under federal disability rights law), until at least one round of facility-wide testing is completed.

- Visitation can resume if residents in a particular area/unit of the facility have no cases of COVID 19 after the first round of testing.
- If the first round of outbreak testing reveals one or more new case of COVID-19 in other areas/units (e.g., new cases in two or more units), facilities should suspend visitations for all residents (vaccinated and unvaccinated), until the facility meets the criteria to discontinue outbreak testing.

LTC Visitor Testing and Vaccination: CDC and CMS encourage (not require) facilities in medium (orange)- or high (red) positivity counties to offer visitor testing. Visitors should not be required to be tested or vaccinated (or show proof of such) as a condition of visitation.

- Facilities should prioritize visitors that visit regularly (e.g., weekly), although any visitor can be tested.
- Facilities may encourage visitors to be tested on their own prior to coming to the facility (e.g., within 2–3 days).
- CMS and CDC encourage visitors to become vaccinated.


Operational Changes for Managing Healthcare Staff during PHE:

CDC Recommendations for “Post-Acute” Providers and Their Staff Now with Vaccinations Available:

- As an employer, you are required to follow federal, state, and local guidance in creating your workplace policy.
- CDC recommends that you maintain a vaccination record and status of all staff.
- Per the Epstein Becker and Green law firm, an employer can ask to affirm employee vaccination of or require proof, what you believe is needed to safely operate your Organization. ecoms@ebg.com

EEOC (Equal Employment Opportunity Commission) as of May 28 permits employers to develop policies which require employees who enter the workplace to receive a COVID-19 vaccination providing those policies comply with the reasonable accommodation provisions of the Americans with Disabilities Act (ADA), as well as Title VII of the Civil Rights Act and any other relevant statute.
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

- Under the May 2021 guidance, employers are permitted to offer incentives to employees to confirm they have received a COVID-19 vaccine, as long as the incentives are not so substantial as to be coercive. Employers may also offer incentives to employees to get their family members vaccinated.

- CDC advises fully vaccinated staff can socialize together in break rooms and conduct in-person meetings without source control or physical distancing. However, if unvaccinated staff are present, everyone should wear source control and unvaccinated staff should physically distance from others.
  - Source control: Well-fitting facemasks, or respirators covering your mouth and nose to prevent spread of respiratory secretions when breathing, talking, sneezing, or coughing.

**Testing:**

**Two Types of Testing Available**

- **Viral testing:** Confirm a current infection and need to be processed in a laboratory and time to results can vary (~1–3 days), but some NAATs are point-of-care tests with results available in about 15–45 minutes.

- **Point of Care Rapid Antigen Testing:** Allows for rapid (15-30 minutes) identification of infected people, thus preventing further virus transmission in the community, workplace (nursing home), etc. May need confirmatory testing with viral test as less sensitive (more false negative results) compared to the viral test, especially among asymptomatic people. [https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html#VaccinationSARSTesting](https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html#VaccinationSARSTesting) May 17, 2021

- Organizations may be able to conduct POC Rapid Antigen Testing: Contact your health department for interpretation of your organization’s ability to conduct testing, required CLIA waiver. [https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/CLIAASA.pdf](https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/CLIAASA.pdf)

**Testing: CDC Recommendations for Staff Diagnostic COVID-19 Testing - fully vaccinated and unvaccinated:**

- Anyone with symptoms of COVID-19, regardless of vaccination status, should receive a viral test immediately.

- CDC recommends that asymptomatic healthcare staff with a higher-risk exposure, regardless of vaccination status, should have a series of two viral tests for SARS-CoV-2 infection. Testing is recommended immediately and 5–7 days after exposure.
  - Higher risk exposure is not wearing appropriate PPE and being within 6 ft of a person for a total of 15 minutes or more in a 24-hr. period, and that person has confirmed COVID-19, or the COVID-19 is confirmed within 14 days of being with that person.

- Fully vaccinated staff providing care in a nursing home may be subject to testing during an outbreak. The federal regulations addressing the scope and frequency of testing are in addition to any state required testing and any facility-specific testing. The federal publication with detail has been updated 4/27/21. [https://www.cms.gov/files/document/qso-20-38-nh.pdf](https://www.cms.gov/files/document/qso-20-38-nh.pdf)
May 27, 2021: Note: Prior receipt of a COVID-19 vaccine will not affect the results of SARS-CoV-2 viral tests.

**Higher Risk Exposure and Fully Vaccinated Staff Work Restrictions:**
- Higher Risk Exposure: Fully vaccinated staff with a higher-risk exposure and who are asymptomatic do not need to be restricted from work for 14 days following their exposure.
- Fully vaccinated staff who travel should continue to follow CDC travel recommendations and requirements, including restriction from work, when recommended for any traveler.


**Ending Isolation**

**Symptom Based Strategy to Discontinue Isolation and Return to Work:**
- Most persons with COVID-19, can end isolation and precautions 10 days after symptom onset and resolution of fever for at least 24 hours, without using fever reducing medications, and with improvement of other symptoms (e.g., cough, shortness of breath).
  - *Symptom onset* is the date symptoms first began, including non-respiratory symptoms.

  Note: Some persons with severe illness may produce replication-competent virus beyond 10 days that warrants extending duration of isolation and precautions for up to 20 days after symptom onset; consider consultation with an infection control expert.

**Ending Isolation of Asymptomatic People Testing Positive for COVID 19, Options**
- At least 10 days have passed since the date of their positive viral test.
- Check with your health department to ensure you know their requirements.

**Options to CDC 14-day Quarantine That Public Health Authorities May Put in Place:**

<table>
<thead>
<tr>
<th>End Quarantine After Day 10 Without Testing</th>
<th>End Quarantine After Day 7 – Diagnostic Testing Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>No evidence of symptoms reported with daily monitoring from the start to day 10.</td>
<td>No evidence of symptoms reported with daily monitoring from the start to day 7.</td>
</tr>
<tr>
<td>Post-quarantine transmission risk ranges from 1% to 10%</td>
<td>End only by negative Pt-PCR testing, specimen may be collected and tested 48 hrs. before day 7, but quarantine cannot be ended before day 7.</td>
</tr>
<tr>
<td>Symptom monitoring continues through day 14, any changes – self-isolate and be tested.</td>
<td>Post-quarantine transmission risk is 5-12%</td>
</tr>
<tr>
<td>Consistent mask use and social distancing, hand cough hygiene, environmental disinfecting, adequate ventilation, avoid crowds.</td>
<td>Required consistent mask use and social distancing, hand cough hygiene, environmental disinfecting, adequate ventilation, avoid crowds.</td>
</tr>
</tbody>
</table>

June 24, 2021, OSHA Emergency Temporary Standard (ETS) effective June 21, 2021

- Applies to home health and hospice, with additional requirements for inpatient hospice. Key is the vaccination status of employees, including in-office. Is your workplace covered by ETS? Decision tool - https://www.osha.gov/sites/default/files/publications/OSHA4125.pdf
- You need a plan, STOP you have this and there is template for the plan you can complete: https://www.osha.gov/coronavirus/ets - right hand column it is a Word document you can fill in – key elements – IMPORTANT by reading the Plan details you can understand the scope of the requirements.
  - Name a COVID 19 Safety Coordinator,
  - Hazard Assessment and Worker Protection related to how and when employees may be exposed to people with suspected or confirmed COVID 19. You will need a policy on determining an employee’s vaccination status. Vaccination remains “encouraged”.
  - Policies and procedures needed are defined, including use of Standard and Transmission based precautions. Review OSHA Mini-respiratory Protection program.
  - PPE must include facemasks, at times face shields, and respirators as needed, provided by the employer. Cloth masks are not approved. Instruction on when to use and how to use. All must be FDA approved.
  - Address: physical distancing, use of barriers, cleaning and disinfecting, ventilation and HVAC systems, health screenings.
  - Employer-employee notification of exposure or illness, with a sample log, as well as removing the employee from work and guidelines for return. Employee training is defined.
  - Employer recordkeeping and working with other employers.
  - Entering private residences! provisions

- Employee rights established – materials in Spanish and English.

OSHA states “In-home healthcare providers have a high risk of infection from working close to patients and possibly their family members or other caregivers in enclosed spaces (e.g., performing a physical examination, helping the patient bathe)”.

NOTE: 21 States and Puerto Rico have OSHA State Plans that meet and exceed federal OSHA and are federal OSHA approved. Check with your State Plan if listed – their guidelines must meet or exceed the above by July 21, 2021.
**PPE:**

- **Accessing PPE, the National Declaration of an Emergency distributes PPE via two (2) sources:**
  - the county and state health departments – access to the national supply stockpile is distributed from health departments on a governor’s requests:
    - Contact your state or local health department to request supplies.
    - Also contact your state associations for information about accessing supplies –
    - When ordering N95 respirators have the model number of the masks fit-tested for your staff. If no model number, provide the manufacturer and year from a mask you have.

- **Update ASPR Regional Health Care Coalitions Areas and Contact Person for Resources:** Health care coalitions (HCC) are groups of health care and response organizations – such as acute care hospitals, emergency medical service (EMS) providers, emergency management agencies, public health agencies, and more – working in a defined geographic location to prepare for and respond to disasters and emergencies. HCCs collaborate to ensure each member has what it needs to respond to emergencies and planned events, including medical equipment and supplies, real-time information, communication systems, and education. Website now allows identification of the coalition serving your area and a contact person.
  - [https://www.phe.gov/Preparedness/planning/hpp/Pages/find-hc-coalition.aspx](https://www.phe.gov/Preparedness/planning/hpp/Pages/find-hc-coalition.aspx) February 2 2021

- **Maximizing PPE:** the CDC website offer specific recommendations to maximize the use of 5 categories of PPE used in the home. Note: information is often written with the inpatient setting in mind. Not all categories will apply to care in the home, but many do. Anticipate how to make these protections work in the home care setting.

**PPE Burn Rate Calculator:** Excel Spreadsheets, instruction video and guidance for each type of PPE.

**Eye Protection:** (NOTE CDC recognizes Face Shields AND Goggles as Eye Protection)

- **Conventional Capacity: Your Organization’s Usual practice with an adequate supply** (Goggles, Face Shield)
  The purpose of eye protection is used to protect staff eyes from exposure to splashes, sprays, splatter, and respiratory secretions for all patient encounters when there is moderate to substantial community transmission of SARS-CoV-2).
  CDC recommends shifting eye protection supplies to reusable devices (i.e., reusable face shields or goggles).
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

- Disposable eye protection (e.g., face shields and goggles, should be removed and discarded after use.
- Re-useable eye protection should be cleaned and disinfected after each patient encounter.

• **Contingency Capacity – expected temporary expected shortage, begin implementing extended use.**
  Extended use of eye protection is a staff member wearing the same eye protection for repeated close contact with several different patients, without removing eye protection between patient encounters.
  - In an expected shortage, a disposable face shield or goggles should be dedicated to one staff member and cleaned and disinfected whenever visibly soiled or when removed and prior to putting it back on.
  - Face shields or goggles should be discarded if damaged (e.g., face shield or goggles can no longer fasten securely to the provider, if staff cannot see clearly, and cleaning does not restore visibility).
  - If staff touch their eye protection or adjust it, they must immediately perform hand hygiene.
  - Staff should leave the patient care area if they need to remove their eye protection.

• **Crisis Capacity: Per CDC these practices do not meet US standards of care but are implemented during known periods of shortages of eye protection for staff.**
  - Use the face shield or goggles beyond manufacturer shelf-life date (most often found on the label of either).
  - Implement extended use for staff whose care activities require prolonged (more than 15 minutes) face-to-face or close contact with a potentially infectious patient for which eye protection is recommended.
  - As an alternative, CDC advises to consider using safety glasses (e.g., trauma glasses) that have extensions to cover the side of the eyes. However, if these have gaps between glasses and the face, they likely do not protect eyes from all splashes and sprays.
  - Exclude staff who are at risk for severe illness from COVID-19 infection from care of patients with suspected or confirmed infection.

Treat glasses and goggles like medical devices - Cleaning per manufacturer guidelines, use gloves to clean, and store in a clean or dirty area so staff know what is clean and what dirty for re-use.


**Gloves**

- **Glove types:** There are two (2) primary types are used in health care, sterile surgical gloves and disposable medical gloves or patient examination gloves, referenced as “Examination” gloves most often.
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

- Home health, home care (private duty), palliation, hospice and home infusion use non-sterile disposable examination gloves. ‘Specialty’ examination gloves often are chemotherapy gloves, which have been tested with chemotherapy agents.

- **Glove product codes** represent the material used in manufacturing; the following is per the FDA:

<table>
<thead>
<tr>
<th>Latex – (LYY)</th>
<th>Vinyl – (LYZ)</th>
<th>Synthetic Polymer – (LZA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitrile – (LZA)</td>
<td>Specialty – (LZC)</td>
<td>Finger Cot – (LZB)</td>
</tr>
</tbody>
</table>


- **Conventional Capacity: Your Organization’s Usual practice with an adequate supply**
  Continued use of FDA-cleared disposable medical gloves following standard and transmission-based and when indicated for other exposures such as handling cleaning chemicals.
  - Reinforce indications and recommended practices for non-sterile disposable glove use, and how and where gloves are to be disposed.
  - Remind staff about indications for gloves use, as well as common situations when gloves may not be needed. (conserve PPE)
  - Prioritize medical gloves for handling chemotherapy agents (chemotherapy gloves) for staff handling chemotherapy and other hazardous drugs. Ensure staff and operations know which drugs meet this qualification to ensure adequate PPE.

- **Contingency Capacity – expected temporary expected shortage.**
  Use gloves past their manufacturer-designated shelf life for training activities
  Non-sterile disposable gloves cleared by FDA are not required to have expiration date labeling; however, some manufacturers choose to designate a shelf life.
  - If a manufactured date is noted, the FDA recommends not using the gloves if more than 5 years since that date.
  - CDC advises using disposable medical gloves that are like FDA-cleared examination gloves and approved under other U.S. or international standards. Examples are shown in the Table at the following website. You would be looking for ‘Examination’ gloves. [https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/gloves.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/gloves.html) (December 23, 2020)

- **Crisis Capacity: Per CDC these practices do not meet US standards of care but are implemented during known periods of gloves shortage. Implement extended use.**
  - Use gloves past their manufacturer-designated shelf life.
  - Prioritize non-sterile disposable gloves for use to protect hands from contact with potentially hazardous substances, including blood and body fluids (e.g., wound care, aerosol generating procedures).
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

- Extended use of disposable medical gloves by staff refers to the practice of wearing gloves without changing them between patients or tasks. Gloves can remain on but must be sanitized between patients to prevent cross transmission from patient to patient.
- During a glove supply crisis gloves can be used up to 4 hours continuously, but must be cleaned between patients to prevent cross transmission from patient to patient.

CDC offers two (2) means for re-use of disposable medical gloves in a time of inadequate supply.

1) Alcohol-based Hand Sanitizer (ABHS): If not visibly soiled, disposable latex and nitrile glove brands maintain their integrity when disinfected for up to six (6) applications of ABHS or until the gloves become otherwise contaminated or ineffective (wear, tears, etc.). Follow hand hygiene guidance for proper application of ABHS.

2) Soap and water can be used to clean donned, disposable medical gloves between tasks or patients. Long-cuffed surgical gloves are recommended as washing may be impractical for short, cuffed gloves where water may become trapped inside the worn gloves which then must be discarded. Disposable medical gloves can be cleaned with soap and water up to 10 times or until the gloves become otherwise contaminated or ineffective. Follow hand hygiene guidance for proper soap and water hand hygiene procedures.

Discard disposable medical or examination gloves always after:
- Visible soiling or contamination with blood, respiratory or nasal secretions, or other body fluids.
- Any signs of damage (e.g., holes, rips) or degradation are observed; and
- Maximum of four (4) hours of continuous use.
- Doffing previously removed gloves should not be re-donned as the risk of tearing and contamination increases. Disposable glove “re-use” should NOT be performed.
- After removing gloves for any reason, hand hygiene should be performed with alcohol-based hand sanitizer or soap and water.


N95 Masks - Particulate filtering facepiece respirators
- There are two types of respirators, standard N95 and surgical N95. You need only N95 or equivalent.
- Respirators are for healthcare staff who need protection from both: 1) airborne droplets and 2) fluid as the close fit is to avoid permeation of both.

KN95 NIOSH (National Institute of Occupational Safety) Sampling identifies KN95 Masks that do not meet basic filtering standards, and in some cases are counterfeit.
- NIOSH developed tests to assess the filter efficiency and penetration (>95%) of a sample of respirators represented as certified by an international certification authority. NIOSH states that usual testing was not done previously due to the respirator shortage associated with COVID-19.
- NIOSH samples identified products that failed filtering tests.
• NIOSH has provided a table at the link below to identify the manufacturer and filtering test results. The table is regularly updated, even daily.
  o NIOSH warns of respirator masks with an ear loop design. NIOSH-approved N95s typically have head bands. Limited assessment of ear loop designs indicate difficulty achieving a proper fit.
  o NIOSH advises that while the manufacturer listed in the table at the link below is the manufacturer of record, NIOSH has been informed that some of these are counterfeit products. Some products with legitimate manufacturer names, showing poor filter penetration results (<95%), are counterfeit products.

Updated NIOSH website:  [https://www.cdc.gov/niosh/npptl/respirators/testing/NonNIOSHresults.html](https://www.cdc.gov/niosh/npptl/respirators/testing/NonNIOSHresults.html)
August 7, 2020

**3M N95 Respirator Masks Fraud Remains Serious**
The FBI, FDA and the 3M company continue to warn about large scale counterfeit 3M N95 masks. The counterfeit masks can be difficult to identify. 3M has taken the following action to reduce the fraud.

• Several 3M respirator masks are equipped with the 3M™ Safeguard™ Product Authentication Process. This allows you to verify if the product you have is authentic.

• Basically, on the bottom of each authentic box of 3M respirators equipped with 3M Safe Guard are two codes a Secure Code and a Lot Code. Both are needed to authenticate the product. If your product is authentic, there is a green check mark message during the authentication check.
  o If any other mark appears, contact 3M anti-fraud hotline (1-800-426-8688 in the U.S.). The hotline is also available to answer any questions or concerns.

• **Conventional Capacity: Your Organization’s Usual practice with an adequate supply of N95 masks**
N95 respirators can be considered for source control by staff to cover one’s mouth and nose to prevent spread of respiratory secretions when they are talking, sneezing, or coughing. When used for this purpose, N95s may be used until they become soiled, damaged, or hard to breathe through. They should be immediately discarded after removal.
  • Extended use strategy for N-95 being used as PPE should **NOT** be used when an organization is in conventional capacity mode. Exhalation Valves on Respirator Masks

**Contingency Capacity Strategies for N-95 Masks**
• Respirators are to be prioritized for staff who are using them as PPE over those staff who are using them for source control.
• Extended use strategy is permitted in contingency capacity, however, the N95 should be discarded immediately after being removed.

**Crisis Capacity Strategies**
• Staff should no longer utilize non-NIOSH approved respirators developed by manufacturers who are not NIOSH-approval holders.
• The number of re-uses of an N-95 should be limited to no more than 5 donnings per device by the same staff member. To ensure adequate respirator performance, staff should always inspect the respirator and perform a seal check upon donning a re-used respirator. N-95 and other disposable respirators should not be shared by multiple staff.
• **Note that each re-use of N95 respirators requires 2 pair of gloves**, a clean pair of gloves when donning or adjusting a previously worn N95 respirator. Then discarding these gloves and performing hand hygiene after the N95 respirator is donned or adjusted and using a new pair of gloves for care.
• **Use of a cleanable face shield or facemask over the respirator** can extend respirator use as it reduces/prevents contamination of the N95 respirator.
• Reuse can also be extended by putting a surgical mask on the patient.


**Staff reuse of N95 Masks with presumptive or confirmed COVID-19 patients**: Two sources of information on reuse:
• NIOSH the National institutes of Occupational Safety [https://www.cdc.gov/niosh/topics/hcwcontrols/recommendedguidanceextuse.html](https://www.cdc.gov/niosh/topics/hcwcontrols/recommendedguidanceextuse.html) (March 27,2020)

**Discard: N95 respirators if:**
• contaminated with patient blood, respiratory or nasal secretions, or other bodily fluids or obviously damaged or becomes hard to breathe through; or
• inadvertent contact is made with the inside of respirator.

**NOTE:** Respiratory pathogens on the respirator surface can potentially be transferred by touch to the wearer’s hands, increasing the risk of causing infection through subsequent touching of the mucous membranes of the face -

**Face Masks**

CDC recommendations for “double masking” is based on the widespread COVID-19 variants some of which appear to spread more quickly and easily than the COVID-19 virus identified in early 2020.

• CDC recommendation are based on 4 factors:
  o How well a mask fits around the nose and below the eyes, and on the sides.
  o How well it filters air.
  o How many layers it has, and?
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

- What mask to wear when, for example around people you do or do not know.

- **Cloth Masks: What to look for:**
  - Look for a cloth mask that is made of multiple layers of tightly woven, breathable fabric.
  - Make sure the cloth mask blocks light from coming through the fabric if held up to a bright light.
  - Does it have gaps around the sides of the face or nose? If so, it fits poorly and can allow respiratory droplets containing the virus to leak in and out around the mask.

  **What you can do:** Layered a cloth mask on top of a medical procedure mask (forming a “double mask”) for better fit and air filtration. Using a mask fitter or brace can also help to the improve fit of a cloth mask.

- **Surgical Masks sold as “disposable face masks” for 1-time community use: What to Look For**
  - Check the labels to ensure that they are made of multi-layered, non-woven material.
  - Look at the fit which is often poor fit as there are gaps around the nose and along the sides of the face, where respiratory droplets containing the virus can leak in and out.

  **What You Can Do:** A medical procedure mask can be layered underneath a cloth mask (forming a “double mask”) for better fit and air filtration. NOTE: a surgical mask should not be layered underneath a surgical mask. A mask fitter or brace can also help to improve fit around the face.

- **KN95 Masks (also known as KN95 Respirators): What to Look For**
  KN95 masks are a type of filtering facepiece respirator that are commonly made and used in China. KN95 masks can be preferred mask to wear in situations that require prolonged close contact (less than 6 ft, for longer than 15 minutes) with people who do not live in the same household, or for people who are at increased risk for severe illness from COVID-19.

  **NOTE:** When fitting properly these masks filter up to 95% of particles. BUT!! many counterfeit (fake) KN95 masks are available, and sometimes it is hard to tell if they meet the right requirements just by looking at them. At least 60% of the KN95 masks evaluated by NIOSH did not meet the requirements that they claim to meet.

  **What You Can Do:** use a KN95 mask identified on the FDA Emergency Use Authorization List
  2/9/21

**Surgical Mask Use:**

- **Conventional Capacity: Your Organization’s Usual practice with an adequate supply**
  Facemasks are used by healthcare staff for 2 general purposes:
  - As PPE to protect their nose and mouth from exposure to splashes, sprays, splatter, and respiratory secretions. When used for this purpose, facemasks should be removed and discarded after each patient.
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

- When used to cover one’s mouth and nose to prevent spread of respiratory secretions when talking, sneezing, or coughing, facemasks may be used until they become soiled, damaged, or hard to breathe through. They should be immediately discarded after removal.

FDA-cleared surgical masks are designed to protect against splashes and sprays and are prioritized for use when such exposures are anticipated, including surgical procedures. Facemasks that are not regulated by FDA, such as some procedure masks, which are typically used for isolation purposes, may not provide protection against splashes and sprays.

- **Contingency Capacity – expected temporary expected shortage – implement extended use.**
  Extended use of facemasks is the practice of staff wearing the same facemask during encounters with several different patients, without removing the facemask between.
  - The facemask is discarded whenever it is removed, and always at the end of each workday.
  - The facemask is removed and discarded if it is soiled, damaged, or hard to breathe through.
  - Staff must take care not to touch their facemask. If they touch or adjust it, they must immediately perform hand hygiene.
  - HCP should leave the patient care area if they need to remove the facemask.
  - Staff who wear a mask to cover one’s mouth and nose to prevent spread of respiratory secretions when talking, sneezing, or coughing may use a cloth mask.
  - Instead of providing a facemask to patients not already wearing their own cloth mask for source control, have them use tissues or other barriers to cover their mouth and nose.

**Crisis Capacity: Per CDC these practices do not meet US standards of care but are implemented during known periods of shortage. Implement limited re-use with extended use.**

- Pairing limited re-use of facemasks with extended use is one staff member using the same facemask for multiple patient contacts but removing it after several contacts and redonning it for further patient contacts.
- Ensure that staff do not touch outer surfaces of the mask during care, and that mask removal and replacement be done in a careful and deliberate manner.
- There is not a known maximum number of uses (donning) of the same facemask.
- The facemask should be removed and discarded if soiled, damaged, or hard to breathe through.
- Facemasks that fasten to the face by using ties may not be able to be undone without tearing and should be considered only for extended use, not re-re-use.
- Facemasks with elastic ear hooks may be the best for re-use.

Staff should leave patient care area if they need to remove the facemask. It should be carefully folded so that the outer surface is inward and against itself to reduce contact with the outer surface during storage. The folded mask can be stored between uses in a clean sealable paper bag or breathable container.

**When No Facemasks are Available:**

- Use a face shield that covers the entire front (that extends to the chin or below) and sides of the face with no facemask.
FAQs: COVID 19 Conference Calls

If neither respirators nor facemasks are available, staff might use cloth masks as a last resort for care of patients with suspected or confirmed diagnosis for which facemask or respirator use is normally recommended. Caution should be exercised when considering this option. Cloth masks should ideally be used in combination with a face shield that covers the entire front (that extends to the chin or below) and sides of the face.


FDA Surgical Face Masks:
The FDA issued an umbrella emergency use authorization (EUA) for certain disposable, single-use surgical masks that meet certain performance requirements for use in any healthcare settings when used by staff to provide a physical barrier to fluids and particulate materials to prevent exposure to respiratory droplets and large particles.
Surgical masks that have been confirmed by the FDA as meeting criteria under the EUA are included in Appendix A as authorized surgical masks and the list is updated regularly.

Gowns: CDC recommending Use of Disposable and Cloth Isolation Gowns
Gowns should be worn for aerosol-generating procedures such as suctioning, nebulizer treatments, and other care activities where splashes and sprays are anticipated, and high-contact patient care activities that provide opportunities for transfer of pathogens to the hands and clothing of healthcare providers.

Conventional Capacity: Usual practice with anticipated adequate supply of gowns
The CDC encourages employers to consider several fluid-resistant and impermeable protective clothing options.
• Nonsterile disposable patient isolation gowns used for routine patient care are appropriate for use by staff when caring for patients with suspected or confirmed COVID-19.
• Reusable (i.e., washable) gowns are also accepted for routine use, and typically made of polyester or polyester-cotton fabrics. Gowns made of these fabrics can be safely laundered after each use according to routine procedures and reused.
  o Routinely inspect gowns for rips or being too thin.
  o Ensure clean gowns stored so clean gowns are easily identifiable.

Emergency Use Authorization for Isolation Gowns: Using ANSI/AAMI PB70 standard disposal gowns:
Level 1 or 2 gowns (non-surgical isolation gowns) is recommended when there is low risk of contamination. https://www.fda.gov/media/138326/download May 20, 2020

Contingency Capacity – Temporary, expected shortage of gown, implement extended use.
Limit the use of isolation gowns:
• To patients with suspected or confirmed SARS-CoV-2 infections during aerosol generating procedures; and
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

- during patient activities that involve close and prolonged contact with the patient or their immediate environment (e.g., dressing, bathing/showering, transferring, providing hygiene, changing linens, changing briefs, or assisting with toileting, device care or use, and wound care).

  NOTE: use of surgical gowns as isolation gowns requires changing gowns between patients and consideration of which surgical gown is used as they provide different levels of protection
  
  https://www.cdc.gov/niosh/npptl/topics/protectiveclothing/

Crisis Capacity: The practices are known not to meet US standards of care but are implemented in the care of patients during known periods of shortages.

- Extend the use of isolation gowns (disposable or reusable) by having staff wear the same gown when interacting with more than one patient housed in the same location and known to be infected with the same infectious disease (e.g., all COVID 19 patients).
  
  o Re-use of the same gown with >1 patient can be considered only if there are no additional co-infectious diagnoses that can be transmitted by contact (such as Clostridioides difficile, Candida Auris).
  
  o A gown being used becomes visibly soiled, it must be removed and discarded or changed.

- Per the CDC, in situations of severely limited or no available isolation gowns, the following clothing can be considered as a last resort for care of COVID-19 patients as single use. None of these options can be considered PPE, since their capability to protect HCP is unknown. CDC recommends using this clothing if it has long sleeves and closures (snaps, buttons) that can be fastened and secured.
  
  - Disposable laboratory coats
  - Reusable (washable) patient gowns
  - Reusable (washable) laboratory coats
  - Disposable aprons
  - Combinations of pieces of clothing can be considered for activities that may involve high amounts of body fluids and when there are no gowns available.


Ongoing FDA Hand Sanitizer Alert: The FDA encourages health care professionals, consumers and patients to report adverse events or quality problems experienced with the use of hand sanitizers to FDA’s MedWatch Adverse Event Reporting program.

- The FDA list to check if your hand sanitizer is a product you should use:

  https://www.fda.gov/consumers/consumer-updates/your-hand-sanitizer-fdas-list-products-you-should-not-use
R

Resources:

• Links to resources found on the Center to Advance Palliative Care (CAPC) website https://www.capc.org/ are free for all providers. COVID 19 resources of interest include:
  • Understanding Distress in the COVID-19 Pandemic
  • A Framework for Coping with Moral Challenges In the COVID-19 Era
• HHS resources for reaching out to diverse communities: https://wecandothis.hhs.gov/
• CMS site dedicated to COVID-19 Vaccine Policies and Guidance: https://www.cms.gov/COVIDvax
• COVID-19 Community Champions – CMS video highlighting the change of long-term care staff from those uncertain about receiving the vaccine to encouraging their peers to do so: https://youtu.be/k0WbAhveyDY
• Medicare publications in several languages: https://www.medicare.gov/about-us/information-in-other-languages
• Information regarding the administration of monoclonal antibodies in the home: https://www.cms.gov/medicare/covid-19/monoclonal-antibody-covid-19-infusion
• Partner resources from CMS including communications, toolkits and resources from HHS and CDC to be used for patient education or training of staff. https://www.cms.gov/outreach-education/partner-resources/coronavirus-covid-19-partner-resources

S

Schools: What we Know about COVID Safety in Schools

• Children can be infected with COVID-19 and spread the virus to others. However, children are less likely to develop severe illness or die from COVID-19.6
• <10% of COVID-19 cases in the United States have been among children and adolescents aged 5–17 years old, about the same % as with other viruses.
  • Younger children (<10 years of age) may be less likely to be infected than adolescents.
• Studies identify those children and adolescents with highest risk for hospitalization:
  • Males, Hispanic ethnicity and black race, average age 8 yrs. old
  • Underlying medical conditions are also more commonly reported among children who are hospitalized or admitted to an ICU.10

In-Person Learning Among Children is NOT associated with Causing Community Transmission of the COVID-19 now evident in studies of in-person schooling Europe and now the US.

• Outbreaks do occur in schools, but multiple studies show that transmission or spread of the COVID-19 virus within school settings is typically lower than – or at least like the levels of transmission or spread in your community - when prevention strategies are in place in schools.
• It is called “layered protection” in schools: masks, physical distancing, handwashing, and respiratory etiquette (cough and sneezing), cleaning, ventilation and contact tracing. For example, if a report a parent ill and it is confirmed, the child quarantines for 14 days with the family.
3 Three Foot Distancing? International and U.S. studies suggest layered protection even with physical distancing of less than 6 ft is still effective in reducing risk for spreading COVID 19.

- Recommendations from WHO and the American Academy of Pediatrics state using a distance of at least 3 feet between students in classrooms could provide a reasonable definition of physical distancing so long as other prevention measures are maximized – the layered protection.


Staff Stress and Compassion Fatigue:
Providing care to others during the COVID-19 pandemic can lead to stress, anxiety, fear, and other strong emotions. How you and your team cope with these emotions can affect your well-being, the care you give to others while doing your job, and the well-being of the people you care about outside of work.

In a Pandemic the Mental Health Issue is Duration: Experiencing or witnessing life threatening events impacts everyone differently. People may experience clinically significant distress or impairment, such as acute stress disorder, PTSD, or secondary traumatic stress (also known as vicarious traumatization). Compassion fatigue may also result from chronic workplace stress and exposure to traumatic events during the COVID-19 pandemic. https://www.cdc.gov/coronavirus/2019-ncov/daily-lifecoping/managing-stress-anxiety.html July 1, 2020

What You Can Do - First Identify It: Recognize the symptoms of stress

- Feeling irritation, anger, or denial
- Fear and worry about your own health and the health of your loved ones, your financial situation or job, or loss of support services you rely on
- Feeling uncertain, nervous, or anxious
- Feeling helpless or powerless
- Lacking motivation
- Feeling tired, overwhelmed, or burned out.
- Feeling sad or depressed
- Having trouble sleeping
- Having trouble concentrating

Learning to Manage Your Reactions:
Focus on 4 Core Components for Self-Management:

1) adequate sleep and rest
2) good nutrition, eat healthy meals,
3) regular physical activity and
4) active relaxation

Talk to Yourself!
• Remind yourself that you are not the only one in an unusual situation with limited resources.
• Identify and accept those things which you do not have control over.
• Recognize that you are performing a crucial role in fighting this pandemic and that you are doing the best you can with the resources available.

Take Control of Aspects of Your Daily Life:
• Keep a consistent daily routine when possible.
• Take breaks during your day to rest, stretch, or check in with supportive coworkers, family, etc.
• Do things you enjoy during non-work hours – the importance of taking time away from work.
• Take breaks from watching, reading, or listening to news stories, particularly about the pandemic.
• ‘Wash Up’ at the end of the day, to ‘put away’ your work.
• Create rituals that allow you to focus your thoughts on letting go of stress or honoring a memory of something positive; seek moments of ‘joy’.
• If you are being treated for a mental health condition, continue with your treatment, and talk to your provider if you experience new or worsening symptoms.

If concerned that you or someone in your household or you work with may harm themselves or someone else here are additional resources. If you share these, you never know when someone may use it.

• National Suicide Prevention Lifeline Toll-free number 1-800-273-TALK (1-800-273-8255)
  o The online Lifeline Crisis Chat is free and confidential. You will be connected to a skilled, trained counselor in your area.
• National Domestic Violence Hotline Call 1-800-799-7233 and TTY 1-800-787-3224
• Disaster Distress Hotline (SAMSHA) (Created for those working during disasters.
  o Call 1-800-985-5990 or text TalkWithUs to 6674.

Other sources American Institute of Stress https://www.stress.org has additional resources.

Staff Anxiety: Leadership, Manager and Supervision -What you can do:
Expect staff to demonstrate increased anxiety, if only as a natural reaction to a sustained period of no predictability that can or does impact all parts of our lives. As leaders you can take action to make a difference for your team! The following is excerpted studies of the impact of the pandemic on health care staff here in the US and the UK.

• Your leadership goal – reduce ambiguity for staff – they just want to know.
  a. Double down on communication
b. Make it open and honest – their concern is financial security, physical safety, etc.

- Acknowledge that you know that their job is stressful, and they are essential workers/heroes. Underscore the value of what they do -they let people stay at home-where we all want to be.
- What roadblocks can you remove? They may have ideas.
- Ensure that your team knows about mental health coverage as part of their benefits or access to these in the community (Noted at the end of the preceding information).
  a. If you have a wellness program, use it for self-care, self-help virtual sessions with experts. Your goal is to reduce the stigma for asking for help.
  b. You may need to talk to some employees about seeking guidance.
- So, what else is effective:
  a. Encourage supervisors and your management to check in with the team about things other than work.
  b. Find more ways to express appreciation.
- c. Resolve conflicts quickly.

Telehealth

Use of Telehealth by Medicare Certified home health agencies.

1. A PRN telecommunication visit order is permissible if it is accompanied by a description of the patient’s medical signs and symptoms requiring the visit and a specific limit on the number of those visits to be made before an additional physician or allowed practitioner order is needed. Orders for care may indicate a specific range in frequency of visits to ensure that the most appropriate level of services is furnished. If a range of visits is ordered the upper limit of the range is considered the specific frequency.

- Comprehensive Assessments and Updates to the Comprehensive Assessment: Audio only or two-way audio-video telecommunication comprehensive assessment or an update to the assessment can be used if it is part of the patient’s plan of care. Telecommunications cannot substitute for in-person visits as ordered on the plan of care.

- Plan of care Changes as the type of visits change, noting which visits will be made in person and which visits will be conducted via telecommunication technology.

- Expectations:
  - Education of patients as to the processes the agency has in place to protect patients as well as home care staff.
  - Not everything can be accomplished per telecommunication when skilled care is required.
  - Work closely with the patient and their family to determine what would reassure them that in-person visits with the staff are safe.
If the patient continues to refuse any in-person visits as per the plan of care, the agency will have to determine if the patient’s medical, nursing, rehabilitation and social needs can be met in their place of residence. Per §484.60 https://www.cms.gov/files/document/03092020-covid-19-faqs-508.pdf (page 57) Updated 6/2/2020

Medicare Hospice Benefit and Telehealth:

- **Hospices can provide services to a Medicare patient receiving routine home care through telecommunications technology** (e.g., remote patient monitoring; telephone calls (audio only and TTY); and 2-way audio-video technology), if it is feasible and appropriate to do so. Only in-person visits are to be recorded on the hospice claim.
- **Face-to-face encounters for purposes of patient recertification** for the Medicare hospice benefit can be conducted via telehealth (i.e., 2-way audio-video telecommunications technology that allows for real-time interaction between the hospice physician/hospice nurse practitioner and the patient). Hospice FAQ Telehealth Answers and Expectations:

- **Initial and Comprehensive Assessments:**
  - Due to the role of the assessment as the foundation of the plan of care and crucial to establishing the hospice-patient relationship, the expectation is that in most situations, the initial and comprehensive assessments would be done in person. Especially for assessment of skin/wound care, uncontrolled pain/symptoms, effective teaching of patient/caregiver medication administration, etc.)
  - It would be up to the clinical judgment of hospice as to whether such technology can meet the patient’s/caregiver’s/family’s needs and the use of technology should be included on the plan of care for the patient and family.

Medicaid and Private Insurance Payment for Telehealth: If hospice and/or home health can bill for telehealth is dependent upon the state flexibilities and the program itself. Research should be conducted to determine when telehealth can be provided and if it is billable.

Telehealth options:

- **Types of telehealth communications:**
  - **Telehealth:** refers to a broader scope of remote health care services than telemedicine as in addition to remote clinician services between a provider and patient/client, it also refers to remote non-clinical services such as clinician to clinician consults, patient education services, and interprofessional care team communications
  - **Telemedicine:** is practice of delivering medicine using technology to deliver care at a distance. A physician/clinician in one location uses a telecommunications infrastructure to deliver care to a patient at a distant site. This is a subset of telehealth.
Remote patient monitoring refers to using technology to gather patient data outside of the traditional health care setting to monitor a patient’s condition while they are at home. This is also a subset of telehealth and includes such devices as glucometers and digital scales.

mHealth: is abbreviated for mobile health and refers to the subset of telehealth that uses mobile technologies. Examples include apps and peripheral devices designed for use on smart phones and tablet. Can be used for videoconferencing, gathering patient data, or providing patient education.

Getting Started:
• What is the state requirement related to patient consent to use telehealth?
  o If verbal consent is obtained, a witness is appropriate, and document consent in the patient’s record.
• Does the organization provide service under who may allow telehealth billing?
• How will telehealth be provided?
• Develop protocols for the delivery of telehealth visits o How will the type of interaction be determined? o How will education be provided to patients/family related to the visits?
  o Who is responsible for scheduling and does a link need to be sent?
  o How will the visit documentation be done? o How will emergency/on call needs be addressed?

Virtual Visit Etiquette
• Start the visit by confirming the patient/family can see and hear. Make a clear verbal transition to the start of the clinical visit. Such as “How are you doing?”
• Let the patient/family know they can interrupt if they need to pause or adjust during the visit. • Confirm that you will call them if sound, or video is lost during the visit
• For the 1st visit provide an overview of the visit.
  o The amount of visit time.
  o What is to be accomplished during the visit • o Discuss any concerns or symptoms being experienced o Review of medications and need for refills. The plan for the next visit
• If calling from home, find a quiet location with a neutral background and good lighting. Wear plain clothes as patterns can cause nausea from the screen.
• Speak slowly and clearly and check every so often to ensure that you are being heard.
• Remember to look at the camera on your own device (not at the screen that has the patient’s video)
• Let the patient/family know when there is 5-10 minutes left and ask if there is anything they want to cover or if they have questions.
• End the visit by summarizing what you heard, what the plan is, reviewing medication needs.
• Inform the patient if the next visit will be a virtual or an in-person visit.

Telehealth Resources:
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

- Health and Human Services [https://telehealth.hhs.gov/providers/getting-started/](https://telehealth.hhs.gov/providers/getting-started/) May 19, 2021
- University of Virginia, Mid-Atlantic Telehealth Resource Center: [https://www.matrc.org/matrc-telehealth-resources-for-covid-19/](https://www.matrc.org/matrc-telehealth-resources-for-covid-19/)

**Tips for Success:**
- Look for changes in care practices to evaluate any potential negative effects on patients.
- Ensure plans of care include telecommunications if staff are using.
- Ensure orders are obtained to reflect any changes in care including the use of telecommunications.
- If utilizing telecommunication, a checklist can help to remember the needs of the visit.

**Travel During the Pandemic:**
The following tables provide direction related to domestic and international travel.
- The guidance presents differences when not vaccinated versus fully vaccinated.

```
<table>
<thead>
<tr>
<th>Domestic Travel Recommendations and Requirements</th>
<th>Not Vaccinated</th>
<th>Fully Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Get tested 1-3 days before travel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Get tested 3-5 days after travel and self-quarantine for 7 days. Self-quarantine for 10 days if you don’t get tested.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-monitor for symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wear a mask and take other precautions during travel</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
```

COVID 19 Vaccines for Staff and for Patients:
The U.S. vaccine approval system ensures that vaccines are as safe as possible. Each vaccine must demonstrate that the benefits outweigh the risks. Find out more about how vaccine safety is ensured at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety.html

COVID 19 – Authorized Vaccinations and Age Groups –
Under the FDA emergency use authorizations, EUAs, the following age groups are authorized to receive vaccination:

- Pfizer-BioNTech: ages ≥12 years and older
  - Vaccine proved 100% effective to prevent COVID-19 in 12-15 age group clinical trial.
  - Most reported side effects in adolescents from clinical trials usually lasted 1-3 days and involved the following (side effects reported more severe following second dose):
    | Pain at the injection site | Tiredness, headache |
    |---------------------------|---------------------|
    | Chills and/or fever        | Muscle and/or joint pain |
- Moderna: ages ≥18 years
  - June 24, 2021. Moderna has submitted data to the FDA to request approval to vaccinate children ages 12-17. FDA is expected to make the decision after the July 4th holiday.
- Johnson and Johnson Janssen: age > 18 y
NOTE: Children and adolescents outside of these authorized age groups should not receive COVID-19 vaccination at this time.

**What to Expect When You Receive the COVID-19 Vaccine:** Each person receives a vaccination card or printout that says which COVID-19 vaccine they received, the date it was received it, and where the person received it.

- Also, each COVID-19 vaccine has its own fact sheet with information about side effects provided on paper or electronically with the first shot.

**Vaccines: What Do We Know and What Are We Still Learning**

- **We know** that the 3 current COVID-19 vaccines in the US are effective at preventing COVID-19 disease, especially severe illness, and death.
- **We know** that other prevention steps such as masks and social distancing help stop the spread of COVID-19, even as vaccines are being distributed.
- **We are still learning** how well COVID-19 vaccines keep people from spreading the disease.
- **We are still learning** how long immunity after vaccination lasts, follow-up booster shots may be required in the winter months. Both Pfizer and Moderna are testing boosters.
- **June 24, 2021:** We are still learning how well COVID-19 vaccines fully protect individuals who have a condition or are taking medications that weakens their immune system; they may **NOT** be fully protected even if they are fully vaccinated. These persons should ask their healthcare provider if they need to continue taking all precautions.


- **We are still learning** how effective the vaccines are against COVID 19 variants.
- **We are still learning** about variants, and how these variants may affect existing vaccines, and tests.

**V-SAFE:**

- CDC has developed **v-safe**, to increase the ability to rapidly detect safety issues with COVID-19 vaccines. V-safe is a smartphone-based, after-vaccination health checker for people who receive COVID19 vaccines. When you receive your vaccination, you find out how to register and you can report symptoms and be reminded of your next dose.


**mRNA Vaccines (Pfizer and Moderna)**
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

**Timing between doses for mRNA vaccination** – the second dose can be given up to 6 weeks (42 days) after the first *if it is not feasible* to follow the recommended intervals. CDC is not proposing delay of the 2nd mRNA vaccine dose, but the data from clinical trials support this range if access is an issue.

https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html June 1 2021

**Pfizer and Moderna Vaccines use new technology: mRNA vaccines:**
mRNA vaccines teach cells how to make a protein—or even just a piece of a protein—that triggers an immune response inside our bodies to COVID-19. These vaccines do not use the live virus that causes COVID-19. The benefit of mRNA vaccines is that those vaccinated gain protection against COVID-19 without risking the serious consequences of getting sick with COVID-19.


**mRNA-COVID 19 Vaccination if the Person had prior COVID-19 Infection.**
Clinical trial data indicate that mRNA COVID-19 vaccines can safely be given to persons with evidence of a prior SARS-CoV-2 infection. This includes persons with symptomatic or asymptomatic COVID infection before the any vaccination or after the first dose. CDC recommends that vaccination be offered to persons regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection.

**June 24, 2021, mRNA New Side Effects- Myocarditis and Pericarditis:**
Increased cases of myocarditis and pericarditis have been reported in the US after mRNA COVID-19 vaccination, particularly in male adolescents and young adults aged 16 and older. There has *not* been a similar pattern observed after receipt of the J&J COVID 19 vaccines.

- Onset is typically within several days after mRNA COVID-19 vaccination, and cases occur more often after the second dose. The severity of myocarditis and pericarditis cases vary. Among cases reported, those who received medical care have responded well to medications and rest.


**mRNA Vaccine Common Side Effects:**
Side effects are normal signs that your body is building protection and responding to the vaccine. These side effects should go away in a few days. Note that side effects most often occur the first day after the second mRNA dose. “Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines” Johanna Chapin-Bardales, PhD, MPH1; Julianne Gee, MPH1; Tanya Myers, PhD, MSc1 JAMA April 5, 2021, doi:10.1001/jama.2021.5374
FAQs: COVID 19 Conference Calls
Updated June 24, 2021

<table>
<thead>
<tr>
<th>Any Systemic Reactions</th>
<th>Pfizer BioNTech (64%)</th>
<th>Moderna (75%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>48%</td>
<td>60%</td>
</tr>
<tr>
<td>Headache</td>
<td>40%</td>
<td>53%</td>
</tr>
<tr>
<td>Myalgia</td>
<td>37%</td>
<td>51%</td>
</tr>
<tr>
<td>Chills</td>
<td>23%</td>
<td>40%</td>
</tr>
<tr>
<td>Fever</td>
<td>21%</td>
<td>37%</td>
</tr>
<tr>
<td>Joint Pain</td>
<td>20%</td>
<td>31%</td>
</tr>
<tr>
<td>Nausea</td>
<td>13%</td>
<td>20%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1%</td>
<td>2%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>6%</td>
<td>8%</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>5%</td>
<td>7%</td>
</tr>
<tr>
<td>Rash Other than Injection Site</td>
<td>1%</td>
<td>2%</td>
</tr>
</tbody>
</table>

• **Important:** Masking and Social Distancing Continues even after Vaccination until more of the population is vaccinated. No current vaccine is 100% effective.

**Vaccine**

**Sources to Access Vaccine in English and Spanish**
Access to a vaccine should not be an obstacle for anyone. Three vaccine tools to share in your community for gaining access to a vaccine:
1) **Online:** Visit [https://www.vaccines.gov/](https://www.vaccines.gov/) (English) or [https://www.vacunas.gov/](https://www.vacunas.gov/) (Spanish) to search and find a vaccine available near you.
2) **Text:** Text your **zip code** to GETVAX (438829) for English or text your zip code to VACUNA (822862) for Spanish to receive three vaccine sites on your phone within seconds.
3) **Call:** National COVID-19 Vaccination Assistance Hotline at 1-800-232-0233 for those who prefer to get information via phone call.

**Vaccine Communication Toolkits**

**Community-Based Organization Toolkit:**
Toolkits can be used to educate healthcare staff or community members about COVID-19 vaccines, raise awareness about the benefits of vaccination and address common questions and concerns. Updated to include adolescent vaccination, with a pediatric healthcare professional toolkit for vaccination.
FAQs: COVID 19 Conference Calls

Updated June 24, 2021

Tips for Effective COVID-19 Vaccine Conversation with Patients Can be Found at:
https://www.cdc.gov/vaccines/covid-19/hcp/engaging-patients.html April 5, 2021

- HCP who has recovered from SARS-CoV-2 infection in the prior 3 months of a higher-risk exposure are also no longer required to quarantine if they remain asymptomatic.
- **NOTE:** HCP who have underlying immunocompromising conditions (e.g., organ transplantation, cancer treatment) which may impact the level of protection provided by the COVID-19 vaccine should continue to implement work restrictions if they have incurred a higher risk exposure. https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-after-vaccination.html
- PPE usage remains unchanged for HCP who are fully vaccinated.

**Designated COVID 19 Vaccinator Status as a Community-Based Organization**
- An HHA or hospice do not need to take any action to administer and bill for the COVID-19 vaccination, either through individual claims or roster bill, you are considered a Medicare mass immunizer. A provider of care at home does need to be approved by your state or local health department to receive the vaccine. Contact the Immunization Program Manager now at your health department. Also check the state list of which disciplines may administer vaccination in the state where the patient receives the vaccine. https://www.phe.gov/emergency/events/COVID19/COVIDvaccinators/Pages/default.aspx May 27, 2021

**Payment Increase for Administering In-Home COVID-19 Vaccination**
- Payment for in-home vaccination of Medicare beneficiaries as of June 8, 2021, has increased by $35.00 making the total payment amount for in-home vaccination about $75. For a two-dose vaccine, the increase results in a total payment of about $150.

This increase accounts for the additional clinical time needed in the home following the vaccine administration and will be geographically adjusted based on where the service is furnished. The vaccine continues to be free of charge with no payment/copay to the beneficiary.

Information about current Medicare payment and billing codes can be found at https://www.cms.gov/medicare/covid-19/medicare-covid-19-vaccine-shot-payment June 8, 2021

A special CMS open door forum was held June 10 at 3 pm for providing information and answering questions about in-home COVID-19 vaccinations for Medicare beneficiaries. Access the following website to find the COVID 19 June 8, 2021, podcast. https://www.cms.gov/Outreach-and Education/Outreach/OpenDoorForums/PodcastAndTranscripts

**Vaccinating Homebound Patients – CDC Recommendations:**
Elements Key to Vaccinating Homebound Patients in home health, hospice, and home care (private duty).  
**NOTE:** Organizations administering vaccine at home do assume additional responsibility, if you do not routinely do this, contact your liability insurer.

- **Training:**
  CDC recommends that healthcare professionals become familiar with the COVID 19 vaccine that will be administered to ensure it is stored, handled, prepared, and administered correctly.

- **Who Do You Train?** Check who is licensed to administer vaccines in your state. Some states may have changed definitions of approved vaccinators during the pandemic in mind, please note if the change in the list is attributable to a state waiver to increase the availability of staff that will end after the PHE.

- **CDC COVID 19 vaccination training and core competencies** can be found at [https://www.cdc.gov/vaccines/covid-19/training.html](https://www.cdc.gov/vaccines/covid-19/training.html) March 4, 2021, for:
  o Healthcare professionals who have administered vaccine in the past 12 months.
  o Healthcare professionals or retired physicians, nurses or practical nurses who are licensed or previously licensed to administer COVID 19 vaccinators but who have not done so in the last 12 months.
  o Support staff (not licensed to administer vaccines) who can assist with vaccine preparation, storage, handling, or transport.

**Pre-Plan for Home Vaccination - What is Involved?**

Estimate the number of doses needed as closely as possible by:

1. Contacting patients or their caregivers in advance to determine who wishes to be vaccinated.
2. Planning to use all doses in a vial - decide on a contingency plan to avoid vaccine waste.
3. Map out travel plans considering the time frames for vaccine use at different temperatures, factor in pre-vaccination preparation time, in-home time including post-vaccination observation.
4. Deciding how to maintain, monitor, and log the temperature of vaccine. Consider using a digital data logger.
5. Identifying what is involved in transporting vaccine - it differs for each vaccine. Understand how you can get access to and use of a “packout” container specific for vaccines. 
   More important about vaccine storage and handling can be found at the following website including warning labels and information about using cars for transport: [https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf](https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf) March 4, 2021
6. Deciding what paperwork that staff bring with them and if it needs to be in different languages? It needs to be specific to the vaccine you are administering.

**Vaccine Administration – What You Need to Consider in Estimating Time in Home:**

1. Assessing patient vaccination status and screening for contraindications and precautions, use the CDC pre-vaccination checklist -even for the second dose,
   a. Observation of at least 15 minutes up to 30 minutes for persons with a history of an immediate allergic reaction (within 4 hours) of any severity to a vaccine or injectable therapy, and persons with a history of anaphylaxis due to any cause.
   b. CDC recommends vaccination providers have at least 3 doses of epinephrine on hand.
2. Educating patients and caregivers,
3. Preparing and administering vaccines, and
4. Documenting the person’s consent to receive the vaccine and the administration in your medical record within 24 hours of administration and reporting data to the relevant system (i.e., immunization information system) no later than 72 hours after administration.

https://www.cdc.gov/vaccines/covid-19/clinical-considerations/homebound-persons.html  Feb 11, 2021

**Important Medication Error Definitions and Action to Take for mRNA Vaccines:**
https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html  Feb 10, 2021

**Allergic Reactions to Vaccine**

**Severe Allergic Reaction - Anaphylaxis - after getting a COVID-19 vaccine.**
- A severe allergic reaction results in an individual’s needs to be treated with epinephrine or an EpiPen® or hospitalization.
- If an individual reports a severe allergic reaction to any ingredient in an mRNA COVID-19 vaccine, they should not receive either of the currently available mRNA COVID-19 vaccines -do not try the other brand if a reaction has occurred to a mRNA COVID-19 vaccine.
- CDC recommends that the individual should not get the second dose.

**Immediate Allergic Reaction: to a COVID-19 vaccine**
- Important definition: *immediate allergic reaction*: Within 4 hours of being vaccinated such as hives, swelling, and wheezing (respiratory distress).
- Anyone who has an immediate allergic reaction—even if it was not severe—to any ingredient in an mRNA COVID-19 vaccine, the CDC recommends that they should not get either of the currently available mRNA COVID-19 vaccines.
- An individual who had an immediate allergic reaction after the first dose of an mRNA COVID-19 vaccine, should not get the second dose. Their doctor may refer them to a specialist in allergies and immunology to provide more care or advice.

**COVID 19 and Allergic Reactions to Other Types of Vaccines**
If an individual has had an immediate allergic reaction—even if it was not severe—to a vaccine or injectable therapy for another disease, they should ask their doctor before getting a COVID-19 vaccine.

**COVID 19 Vaccine and Allergies Not Related to Vaccines**
- CDC recommends that people with a history of severe allergic reactions not related to vaccines or injectable medications—such as food, pet, venom, environmental, or latex allergies—get vaccinated.
- People with a history of allergies to oral medications or a family history of severe allergic reactions can also get vaccinated.

**COVID 19 and previous allergic reaction to polyethylene glycol (PEG) or polysorbate**
Polysorbate is not an ingredient in either mRNA COVID-19 vaccine but is closely related to PEG, which is in the vaccines. People who are allergic to PEG or polysorbate should not get an mRNA COVID-19 vaccine.
Viral Vector Vaccine: Johnson & Johnson Janssen COVID 19 Vaccine:

- Viral vector vaccines use a modified version of a different virus (the vector) to deliver instructions to our cells. For COVID-19 viral vector vaccines, the vector (not the virus that causes COVID-19, but a harmless virus) enters a cell in the body and then use the cell’s machinery to produce a harmless piece of the virus that causes COVID-19 called a spike protein that is only found on the surface of the virus that causes COVID-19.
- The cell displays the spike protein on its surface, and our immune system recognizes it does not belong there. This triggers our immune system to begin producing antibodies and activating other immune cells to fight off what it thinks is an infection. As a result, our bodies protect us against future infection with the virus that causes COVID-19.
- Viral vectors cannot cause infection with COVID-19 or with the virus used as the vaccine vector.
- The genetic material delivered by the viral vector vaccine does not integrate into or affect a person’s DNA.
- The J&J vaccine is 85% effective in preventing severe disease across all regions in the clinical trials and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.
- Side effects of vaccination from the clinical trials: injection site pain, headache, fatigue, myalgia, nausea, fever, injection site erythema and injection site swelling. Severe allergic reactions have occurred in clinical trials.
- Women younger than 50 years old should be made aware of a rare risk of blood clots with low platelets following vaccination and the availability of other COVID-19 vaccines where this risk has not been observed. Symptom onset is reported 6 to 15 days after vaccination. [Fact sheet for healthcare providers administering Janssen COVID 19 Vaccine](https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-HCP-fact-sheet.pdf) April 23, 2021

What Symptoms to watch if You Receive a J&J Vaccination seek medical care right away if you develop any of the following symptoms of a blood clot with low platelets:

<table>
<thead>
<tr>
<th>Severe headache</th>
<th>Backache</th>
<th>Blurred vision</th>
<th>Fainting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizures</td>
<td>Severe chest pain</td>
<td>Shortness of breath</td>
<td>Swelling in a leg</td>
</tr>
<tr>
<td>New or easy bruising</td>
<td>Petechiae</td>
<td>Severe abdominal or stomach pain</td>
<td></td>
</tr>
</tbody>
</table>

Co-Vaccination

The COVID-19 vaccine series should routinely be administered alone, with a minimum interval of 14 days before or after administration with any other vaccine. If benefits of co-administration outweigh the Potential unknown risks of vaccine coadministration (e.g., tetanus), the interval could be a shorter period. [https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-)


TB testing and mRNA COVID-19 vaccination:
Not enough is yet known about the potential impact of mRNA vaccines on immune responses to know if the COVID-19 mRNA vaccine has a potential effect on TST or IGRA test results during the first 4 weeks after COVID-19 vaccination.

For healthcare staff or patients who require baseline TB testing (at onboarding or entry to facilities) at the same time they are to receive a COVID-19 mRNA vaccine, CDC recommends:
- Perform TB symptom screening on all healthcare personnel or patients.
- If using IGRA, draw blood prior to COVID-19 mRNA vaccination.
- If using TST, place prior to COVID-19 mRNA vaccination.
- If COVID-19 mRNA vaccination has already occurred, defer TST or IGRA until 4 weeks after completion of 2-dose COVID-19 mRNA vaccination.

Waivers:
Types of 1135 waivers are issued during the Public Health Emergency (PHE). All waivers are effective March 1, 2020 and end effective when the federal Public Health Emergency ends.

- Federal Blanket Waivers: Publicly announced by CMS and applicable to all providers by Medicare benefit type. Examples include the home health and hospice waivers.

- State Medicaid waivers: States may request waivers of Medicaid regulations by contacting CMS. Over 48 states have requested waivers. To the following website, find your state, click on what is a letter to the state, scroll past the letter and you will find the details of the waiver.

Please join CHAP on our COVID 19 Conference Calls in 2021:
The last regularly scheduled COVID 19 conference call is now planned for Thursday July 8, 2021, Thursdays 3-4:00 PM ESDT Call in: 646-307-1479, or toll-free 877-304-9269 • Participant code: 246854#

As COVID 19 information is updated, CHAP will provide the information VIA?

Thank you for your dedication and be well!